

Market Announcement

7 May 2021

Health House International Limited (ASX:HHI) – Trading Halt

Description

The securities of Health House International Limited ('HHI') will be placed in trading halt at the request of HHI, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 11 May 2021 or when the announcement is released to the market.

Issued by

Vanessa Nevjestic

Adviser, Listings Compliance (Perth)



7 May 2021

Australian Securities Exchange Limited
40 Central Park
152 – 158 St Georges Terrace
PERTH WA 6000

Attention: Daniel Nicholson
By email only: Daniel.Nicholson@asx.com.au

Dear Sir,

TRADING HALT REQUEST

In accordance with ASX Listing Rule 17.1, Health House International Limited ('the Company', ASX: **HHI**) requests the granting of a trading halt in HHI's ordinary securities listed on the Australian Securities Exchange (ASX).

The Company provides the following information in relation to the request:

1. The trading halt is requested pending an announcement by the Company in relation to a material acquisition;
2. The Company requests an immediate trading halt and anticipates that the trading halt remain in place until the earlier of the commencement of trading on Tuesday, 11 May 2021 or the making of an announcement in respect to a material acquisition; and
3. HHI confirms that it is not aware of any reason why a trading halt should not be granted or any other information necessary to inform the market about the trading halt.

Yours sincerely

Tim Slate
Company Secretary

ABOUT HEALTH HOUSE

Health House International is an international pharmaceutical distributor specialising in, but not limited to, the distribution of medicinal cannabis products across Australasia, United Kingdom and Europe.

The Company is a fully licenced and regulated specialised importer, exporter, consolidator and distributor of medicinal cannabis products currently distributing 11+ medicinal cannabis products to pharmacies, prescribers, specialist medicinal cannabis clinics and researchers across Australasia. With its Wholesale Dealers and Controlled Drugs licences the Company supplies pharmacies, hospital, government departments, veterinarians and other wholesalers with medicinal cannabis and general pharmaceutical products in the UK and Europe.